Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus LUPRON DEPOT PED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus LUPRON DEPOT PED KIT.
LEUPROLIDE ACETATE vs LUPRON DEPOT-PED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Upon continuous administration, it suppresses pituitary gonadotropin secretion by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently reducing sex steroid (testosterone and estrogen) production in the gonads.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
Prostate cancer: 7.5 mg IM once monthly or 22.5 mg IM once every 3 months or 45 mg SC once every 6 months. Central precocious puberty: 50 mcg/kg/day SC or 7.5 mg IM once monthly. Endometriosis: 3.75 mg IM once monthly or 11.25 mg IM once every 3 months.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following intravenous administration; after subcutaneous depot formulations, the effective half-life is extended due to slow release, with a terminal half-life of about 3-4 weeks for the 1-month depot.
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Renal: approximately 5% as unchanged drug; hepatic metabolism accounts for the majority of clearance, with metabolites excreted renally and fecally; biliary excretion is minimal.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Category D/X
Category C
GnRH Agonist
GnRH Agonist